4D Molecular Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-160.9	-140.11	-160.87	-100.84	-107.49	-71.32
Depreciation & Amortization	7.93	7.63	6.71	5.75	3.88	3.02
Stock-Based Compensation	19.48	22.02	26.12	19.67	17.12	13.8
Other Adjustments	-3.41	-4.79	-7.08	-1	1.14	0.9
Change in Receivables	-	-	-	-	0.05	1.44
Changes in Accounts Payable	10.54	6.77	0.87	0.9	-1.64	2.29
Changes in Accrued Expenses	6.34	8.15	6.52	3.37	2.49	0.69
Changes in Unearned Revenue	1.19	-0.21	0.07	-0.72	-3.13	-14.72
Changes in Other Operating Activities	-9.48	-8.54	-6.93	-2.92	0.9	-5.23
Operating Cash Flow	-129.45	-109.08	-134.59	-75.79	-86.69	-69.13
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	0.11	-0.54	-3.79	-2.77	-11.54	-9.11
Purchases of Investments	-342.26	-442.82	-467.65	-54.8	-153.31	-168.57
Proceeds from Sale of Investments	286.12	350.38	169	173.29	147.8	5
Investing Cash Flow	-56.03	-92.97	-302.44	115.72	-17.05	-172.68
Issuance of Common Stock	2.66	112.96	337.25	156.83	3.55	118.09
Net Common Stock Issued (Repurchased)	2.66	112.96	337.25	156.83	3.55	118.09
Other Financing Activities	-	-	-	-	-0.47	-
Financing Cash Flow	124.44	112.96	337.25	156.83	3.09	118.09
Net Cash Flow	-61.04	-89.1	-99.77	196.76	-100.65	-123.73
Free Cash Flow	-129.34	-109.62	-138.37	-78.56	-98.22	-78.24
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-146.58%	-128.65%	-373976.00%	-379.11%	-3139.05%	-433.77%
Free Cash Flow Per Share	-2.12	-1.89	-2.57	-2.01	-3.04	-2.82
Levered Free Cash Flow	-144.27	-126.85	-157.41	-97.23	-116.53	-94.38
Unlevered Free Cash Flow	-162.92	-146.29	-184.39	-109.26	-119.07	-94.4

SEC Filings: 10-K · 10-Q